저분자 수탁개발제조기관(CDMO)의 성장 기회 : 세계(2026-2031년)

The global small-molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high-volume commodity generics toward specialized development and manufacturing capabilities in high-potency APIs (HPAPIs), antibody-drug conjugate (ADC) payloads and linkers, complex oral solids, and sterile injectable products. Supported by sustained outsourcing across development and commercial stages, the small-molecule CDMO market is projected to grow at a steady mid-single-digit CAGR through 2031, reflecting the sector’s continued relevance in both essential and innovative therapies.

Across the ecosystem, multiple strategic imperatives—including geopolitical realignment, supply chain sovereignty, regulatory tightening, sustainability mandates, and technology disruption—are reshaping competitive dynamics. Sponsors increasingly expect CDMOs to offer rapid tech transfer, advanced process science, flexible small-batch and late-stage capacity, regulatory reliability, and geographically diversified manufacturing footprints. Capacity constraints persist in HPAPI manufacturing, ADC-related chemistries, and aseptic fill-finish, driving accelerated investment in North America and Europe, while Asia-Pacific players continue to strengthen their position through scale, cost competitiveness, and gradual movement into more regulated supply segments.

The study identifies several high-impact growth opportunities for CDMOs, including expansion of HPAPI and ADC payload-linker capabilities aligned with oncology pipelines; modernization and automation of sterile fill-finish infrastructure; integration of particle engineering, solubility enhancement, and continuous manufacturing for complex oral solids; and adoption of digital, ESG-aligned operating models that enhance transparency and execution reliability. CDMOs that proactively invest in these capabilities, secure long-term capacity partnerships, and offer integrated development-to-commercial platforms will be best positioned to capture premium growth. For pharmaceutical sponsors, investors, and policy stakeholders, the findings provide a clear roadmap for value creation in an increasingly strategic and resilience-driven small-molecule manufacturing landscape.

The study period is 2023 to 2031, with 2025 as the base year and 2026 to 2031 as the forecast period. Market segmentation is by:

• Product Type: Active pharmaceutical ingredients (APIs, including HPAPIs and intermediates) and finished dosage formulations (oral solids, liquids, semi-solids, injectables, others)
• Service Type: Clinical and commercial manufacturing
• Region: North America, Europe, APAC, Latin America & the Caribbean, and the Middle East & Africa

Scope and Segmentation

• Scope of Analysis
• Segmentation

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8TM
• The Impact of the Top 3 Strategic Imperatives on the Small-Molecule CDMO Industry

Growth Opportunity Analysis

• Pharmaceutical: Small-Molecule Revenue Forecast and Share
• Pharmaceutical Industry: Equity Returns and Volatility Trends
• Pharmaceutical Funding Trends
• Pharmaceutical Industry: Early-Stage Funding and Licensing Activity
• Pharmaceutical Industry: M&A Activity in 2025
• Patent Expiries and Implications for CDMOs
• Pharma Revenue Growth by Modality
• Small-Molecule Modalities: Development and Maturity Curve
• Specialty Small-Molecule Pipeline
• CDMO Demand Volatility and Capacity Management Dynamics
• Growth Drivers
• Growth Restraints
• Global Trends Impacting the Small-Molecule CDMO Industry
• Industry Trends Impacting the Small-Molecule CDMO Industry
• Business Model: Selective Evolution within a Fee-for-Service Dominated Market
• Structured Accountability Models in Small-Molecule CDMO Partnerships
• Attractiveness of Pricing Models
• Collaboration Success Criteria

Competitive Environment

• Competitive Environment
• Key Competitors
• Tier I: Competitive Strategies
• Tier II: Competitive Strategies
• Tier III: Competitive Strategies
• Tier IV: Competitive Strategies
• Tier V: Competitive Strategies

Analysis by Product Type- Active Pharmaceutical Ingredient (API)

• Generic API
• Innovator API
• API: M&As
• API: Capacity Expansions
• API: Investments

Analysis by Product Type: Finish Dosage Form (FDF)

• Oral
• Oral: M&As and Investments
• Oral: Capacity Expansions
• Liquids and Semi-Solids
• Liquids and Semi-Solids: M&As and Investments
• Liquids and Semi-Solids: Capacity Expansions
• Injectables
• Injectables: M&As and Investments
• Injectables: Capacity Expansions
• Others
• Others: M&As and Investments
• Others: Capacity Expansions

Analysis by Service Type

• Clinical
• Commercial

Analysis by Region

• North America
• North America: Notable Investments
• Investment Flow by Country
• Europe
• Asia-Pacific
• Latin America and Caribbean
• The Middle East and Africa

Growth Opportunity Universe

• Growth Opportunity 1: Integrated HPAPI, Payload, and Linker Manufacturing for Antibody-Drug Conjugates
• Growth Opportunity 2: Sterile Fill-Finish Capacity for High-Value Injectables
• Growth Opportunity 3: Integrated FDF Capabilities for Complex Oral Solids

Appendix & Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer